Table 3.
Mean Change in Mesopic, High-Contrast UNVA Letters from Baseline over the 2-Day Dosing Period in the Short-term Study
| Treatment Group Pilo % |
Oxy 0% | Oxy 0.0125% | Oxy 0.05% | Oxy 0.125% | Fixed Combination |
|---|---|---|---|---|---|
| Pilo 0% | |||||
| N | 39 | 38 | 39 | 39 | 40 |
| LS Mean (SE) | 1.12 (0.61) | 1.27 (0.62) | 1.62 (0.61) | 1.02 (0.61) | |
| Mean (SD) | 1.00 (2.70) | 1.13 (3.15) | 1.48 (3.77) | 0.85 (4.91) | 3.01 (3.60) |
| Median | 1.00 | 0.70 | 1.20 | 0.90 | 2.40 |
| Min, Max | −4.6, 7.5 | −6.5, 8.5 | −6.8, 11.3 | −18.2, 10.5 | −2.8, 13.3 |
| Pilo 0.5% | |||||
| N | 37 | 35 | 35 | 35 | 35 |
| LS Mean (SE) | 3.40 (0.63) | 3.96 (0.65) | 4.89 (0.65) | 4.27 (0.65) | |
| Mean (SD) | 3.20 (2.93) | 3.75 (4.12) | 4.68 (3.92) | 4.06 (3.64) | 4.61 (4.57) |
| Median | 3.40 | 3.20 | 6.10 | 4.10 | 4.20 |
| Min, Max | −3.0, 9.1 | −3.8, 11.5 | −3.6, 13.7 | −2.3, 13.6 | −1.9, 17.8 |
| Pilo 1.0% | |||||
| N | 42 | 41 | 41 | 41 | 42 |
| LS Mean (SE) | 5.25 (0.59) | 5.36 (0.60) | 5.17 (0.60) | 5.34 (0.60) | |
| Mean (SD) | 5.09 (4.39) | 5.22 (3.54) | 5.05 (3.86) | 5.22 (3.47) | 5.07 (4.93) |
| Median | 4.75 | 4.60 | 4.80 | 4.70 | 3.80 |
| Min, Max | −2.5, 16.2 | −0.5, 13.3 | −3.1, 13.7 | −2.2, 11.4 | −4.1, 19.6 |
| Pilo 1.5% | |||||
| N | 36 | 36 | 35 | 37 | 37 |
| LS Mean (SE) | 5.11 (0.64) | 6.65 (0.64) | 4.83 (0.65) | 5.64 (0.63) | |
| Mean (SD) | 5.01 (4.10) | 6.56 (4.79) | 4.73 (3.30) | 5.49 (4.36) | 5.18 (4.23) |
| Median | 4.40 | 6.50 | 4.90 | 4.6 | 5.00 |
| Min, Max | −5.9, 14.4 | −1.1, 22.0 | −1.5, 10.6 | −4.8, 18.3 | −1.4, 16.2 |
LS = least squares; Oxy = oxymetazoline; Pilo = pilocarpine; SD = standard deviation; SE = standard error; UNVA= uncorrected near visual acuity.